ImmunityBio, Inc.
IBRX
Clasificación en acciones
#2233
ImmunityBio, Inc. is a clinical-stage biotechnology firm, founded in 2014 and... ImmunityBio, Inc. is a clinical-stage biotechnology firm, founded in 2014 and based in San Diego, California. The company is focused on developing groundbreaking therapies and vaccines designed to treat a wide array of cancers and infectious diseases. Its innovative approach relies on a comprehensive suite of immunotherapy and cell therapy platforms. These advanced technologies include novel antibody-cytokine fusion proteins, synthetically engineered immunomodulators, cutting-edge vaccine technologies, natural killer (NK) cell therapies, and strategies that harness the adaptive (T-cell) immune system. ImmunityBio currently has several therapeutic candidates in advanced clinical development, with agents undergoing Phase II or III trials. These investigational treatments are aimed at various liquid and solid tumors, such as bladder, pancreatic, and lung cancers, as well as significant infectious pathogens including SARS-CoV-2 and HIV. The company actively engages in strategic partnerships, holding collaboration agreements with esteemed organizations like the National Cancer Institute, the National Institute of Deafness and Communication Disorders, and Amyris, Inc. Additionally, ImmunityBio has secured licensing agreements with numerous entities, including CytRx Corporation, EnGeneIC Pty Limited, GlobeImmune, Inc., Infectious Disease Research Institute, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc.
Precio por acción
$8.55
Última sincronización: 2026-10-19
Capitalización bursátil
$9.06B
Cambio (1 día)
-6.84%
Cambio (1 año)
249.08%
País
US
Comercio ImmunityBio, Inc. (IBRX)
Categoría
Healthcare
Ganancias de ImmunityBio, Inc. (IBRX)
Ganancias en Jun 2026 TTM: $-992.58M
Secondo gli ultimi rapporti finanziari di ImmunityBio, Inc., gli utili attuali della società sono $-992.58M. Nel 2023, la società ha registrato un utile di $-583.89M, una disminución en comparación con agli utili del 2022, che erano di $-417.29M. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Historial de ganancias de ImmunityBio, Inc. desde 2013 hasta 2026
Ganancias al final de cada año
| Año | Ganancias | Cambiar |
|---|---|---|
| 2026 (TTM) | $-992.58M | 139.96% |
| 2024 | $-413.65M | -29.16% |
| 2023 | $-583.89M | 39.93% |
| 2022 | $-417.29M | 19.28% |
| 2021 | $-349.84M | 54.77% |
| 2020 | $-226.03M | 243.07% |
| 2019 | $-65.89M | -31.89% |
| 2018 | $-96.73M | -0.19% |
| 2017 | $-96.92M | -20.16% |
| 2016 | $-121.38M | -48.82% |
| 2015 | $-237.18M | 3,718.05% |
| 2014 | $-6.21M | 203.62% |
| 2013 | $-2.05M | 0.00% |
Ganancias de empresas similares o competidoras
| Empresa | Ganancias | Diferencia de ganancias | País |
|---|---|---|---|
| $5.27B | -631.43% |
US
|
|
| $-3.09B | 211.01% |
US
|
|
| $-4.02B | 304.62% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -296.52% |
NL
|
